Publisher: Cairo Univeristy (Total: 1 journals)   [Sort by number of followers]

Showing 1 - 1 of 1 Journals sorted alphabetically
Research in Oncology     Open Access  
Similar Journals
Journal Cover
Research in Oncology
Number of Followers: 0  

  This is an Open Access Journal Open Access journal
ISSN (Print) 2357-0687 - ISSN (Online) 2357-0695
Published by Cairo Univeristy Homepage  [1 journal]
  • Genetic Variants of MicroRNA-146a and MicroRNA-196a2 are Associated with
           Poor Outcome but not ...

    • Abstract: Background: Polymorphisms in microRNAs (miRNAs) encoding genes are involved in carcinogenesis. However, their relation to lymphomagenesis is still unclear.Aim: To investigate the influence of miRNA-146a rs2910164 G/C polymorphism and miRNA-196a2 rs11614913 C/T polymorphism on risk and clinical outcome of high-grade B cell non-Hodgkin lymphoma (HGB-NHL).Methods: Seventy-five patients with HGB-NHL and 100 matched controls were screened for miRNA-146a rs2910164 G/C and miRNA-196a2 rs11614913 C/T polymorphisms by Polymerase Chain Reaction-Restriction Fragment length Polymorphism (PCR-RFLP).Results: The two studied miRNA polymorphisms were not associated with the risk of NHL. The GG genotype of miRNA-146a rs2910164 was associated with a worse disease-free survival (DFS) compared to the GC and CC genotypes (HR =5.7; 95% CI=1.05-31.09; p=0.044). The miRNA-196a2 rs11614913 CC genotype was associated as well with worse DFS compared to the CT and TT genotypes (HR=10.37; 95% CI=1.80-59.62; p = 0.009). No significant association was found between the studied miRNA polymorphisms and patients’ overall survival.Conclusions: miRNA-146a rs2910164 G/C and miRNA-196a2 rs11614913 C/T polymorphisms may be associated with shorter DFS in HGB-NHL.
      PubDate: Thu, 05 May 2022 22:00:00 +010
       
  • A review on the Dual Role of SOCS3 in Cancer

    • Abstract: Background: Aberrant proliferation is a hallmark of cancer. Cellular proliferation mechanisms and various cytokines contribute to the progression of cancer. The tumor suppressor protein Suppressor of Cytokine Signalling 3 (SOCS3), which acts via the JAK/STAT pathway, have a role in the progression of cancer.Aim: To explore the role of SOCS3 in all the hallmarks of cancer. To exhibit SOCS3 action on proliferation pathways and immune aspect affecting cancer progression.Methods: The PubMed database was searched using the keywords proliferation, SOCS3, JAK/STAT, interleukins, and tumor suppressor. Articles relevant to SOCS3 were considered for this review.Results: In this review, we have illustrated the dual action of SOCS3, which inhibits various proliferative mechanisms and affects certain interleukins that counterbalance the progression of cancer. In addition, SOCS3 affects all the hallmarks of cancer.Conclusion: We hope that this review will stimulate further investigation of SOCS3, which has the potential to become a new target for the pharmacological treatment of various cancers in the future.
      PubDate: Mon, 04 Apr 2022 22:00:00 +010
       
  • Outcome and Safety of Cytoreductive Surgery (CRS) and Hyperthermic
           Intraperitoneal Chemotherapy ...

    • Abstract: Background: Peritoneal sarcomatosis (PS) is an aggressive disease; cytoreductive surgery (CRS) could be curative. Aim: Can the addition of hyperthermic intraperitoneal chemotherapy (HIPEC) +/- intraoperative radiation therapy (IORT) overcome treatment failure with an overall survival benefit. Methods: Retrospective review of the medical records of patients with PS treated by CRS, HIPEC and IORT at a comprehensive cancer center in the period between 2011-2016. Results: Twenty-four patients were identified. Fifteen were men and their median age was 58 years. Liposarcoma was the most frequent diagnosis (50%). Cytoreduction completeness (CC) score 0/1 was achieved in 19 patients, with a median pathological peritoneal cancer index (pPCI) of 12. Intraoperative radiation therapy was given in 16 patients. Eight patients developed grade III-IV Clavien-Dindo post-operative complications and 1 patient died 5 days post operative. Adjuvant chemotherapy was received in 9 patients. After a median follow-up of 28.5 months, the median PFS was 20.7 months, while the estimated 2- and 4-year PFS were 37.1% and 19.1%, respectively. The median OS was 176.5 months and the estimated 2- and 4-year OS were 95.8% and 79.8%, respectively. In the univariate analysis, the PFS differed significantly according to the CC score only. The median PFS for patients with CC 0-1 was 23.8 vs. 8.8 months for those with CC 2-3 (p = 0.027). Conclusions: The addition of HIPEC and IORT to CRS in the management of PS is feasible and safe. Comparing our results to several studies, this multimodality approach seems to improve local and regional control rates. A larger cohort of patients is needed for further evaluation and to give a concrete conclusion.
      PubDate: Thu, 10 Feb 2022 22:00:00 +010
       
  • Study of the Efficacy and Multidrug Resistance Using Gold
           Nanoparticles-Based Drug Delivery ...

    • Abstract: Background: Cisplatin is the main chemotherapy in the treatment of non-small-cell lung cancer (NSCLC) combined with gemcitabine or other agents. Aim: The aim of this study was to evaluate in vitro the anti-tumor efficacy and multidrug resistance of gold nanoparticles (GNPs) conjugated with cisplatin and /or gemcitabine for the treatment of NSCLC. Methods: MTT cytotoxicity assay was carried out in NSCLC cell line (A549). Cell viabilities were determined after treatment with different concentrations of cisplatin, gemcitabine, GNPs-cisplatin or GNPs-gemcitabine. Combinations of variable ratios (1:1, 1:2, 2:1, 1:9, 9:1) of cisplatin + gemcitabine, GNPs-cisplatin + gemcitabine, cisplatin + GNPs-gemcitabine or GNPs-cisplatin + GNPs-gemcitabine were also tested. The Combination Index was computed for each combination concentration ratio and dose to know the best synergistic effect. Histological changes and multidrug resistance were studied. Results: The 1:1 ratio combination concentration showed the highest synergistic effect among all concentration ratios (p < 0.001). Multidrug resistance revealed that the percent efflux of the GNPs-cisplatin + GNPs-gemcitabine combination with a 1:1 ratio was the minimal in comparison to the other drug combinations. Conclusion: The use of nanoparticles functionalized with cytotoxic drugs such as cisplatin or gemcitabine alone or in combination enhances their antitumor effect and decreases the multidrug resistance in NSCLC cell line.
      PubDate: Tue, 30 Nov 2021 22:00:00 +010
       
  • First Relapse of Acute Lymphoblastic Leukemia in Children in Upper Egypt:
           Survival Outcome and ...

    • Abstract: Background: Relapse is the main reason of treatment failure in childhood acute Lymphoblastic leukemia (ALL). Aim: To study the treatment outcome of first ALL relapse in response to two different reinduction regimens and prognostic factors predicting outcome. Methods: A retrospective study that included 82 children with ALL in the 1st relapse from two tertiary oncology centers in Upper Egypt. Patients were treated according to the St. Jude ALL-R16 protocol. Seventeen patients were treated with a standard reinduction (regimen 1) and 65 were treated with a modified reinduction regimen in which anthracycline was added and asparaginase was reduced to 9 doses (regimen 2). Response, survival and prognostic factors were analyzed. Results: Second, complete remission (CR2) was achieved in 57% of all patients (65% with regimen 2 vs. 29% with regimen 1, p = 0.009).  FLAG regimen resulted in achieving CR2 in all patients with reinduction failure. Treatment related mortality was more common with regimen 2 than with regimen 1 (34% vs. 12%, respectively). For all patients, the 2-year overall and event-free survival rates were 30% and 25%. In multivariate analysis, high initial total leukocytic count, isolated medullary relapse, regimen 1 and very early relapse were independently associated with worse event free survival (p = 0.031, 0.017, 0.037 and 0.001; respectively). Conclusions: The overall outcome of treatment of first ALL relapse in children in our region is poor. New intensive chemotherapy regimens may help in improving the treatment outcome.
      PubDate: Tue, 30 Nov 2021 22:00:00 +010
       
  • Evaluation of Sentinel Lymph Node Biopsy After Primary Chemotherapy as
           Part of De-Escalation of ...

    • Abstract: Background: Sentinel lymph node biopsy (SLNB) after primary chemotherapy for node-positive breast cancer patients has been gaining popularity as part of the de-escalation of treatment. Aim: The 1ry aim was to assess the surgical outcome of node-positive patients who received primary chemotherapy followed by SLNB. A 2ry aim was to determine the rate of sentinel lymph node identification using the patent blue dye only technique. Methods: A prospective study that included 86 patients with invasive breast cancer and axillary lymph nodes metastasis as proved by ultrasound scan guided core biopsy. Following the completion of primary chemotherapy, sentinel lymph node biopsy was carried out for all patients at the time of breast surgery using the patent blue dye technique. Patients with negative SLNB underwent no further axillary procedure. Completion of axillary lymph node clearance was performed for positive SLNB patients. Results: The sentinel lymph node identification rate using the patent blue dye directed technique was 79%. Sixty-seven (78%) patients underwent wide local excision, and 35% did not need completion of axillary lymph node clearance due to downstaging following primary chemotherapy. Conclusions: Sentinel lymph node biopsy following primary chemotherapy for invasive breast cancer appears to be a safe, reliable technique, with an acceptable identification rate, even when using the patent blue dye technique only.
      PubDate: Tue, 30 Nov 2021 22:00:00 +010
       
  • Factors Influencing the Response Rate and Survival of Testicular Germ Cell
           Tumors: A Single ...

    • Abstract: Background: Testicular germ cell tumors (TGCTs) are the most common cancer in young adult males, and they represent one of the most curable solid tumors. The treatment modalities of different stages are variable among centers. Aim: To describe the management of TGCTs and its outcome in an Egyptian cancer center. Methods: The medical records of patients with TGCT treated between January 2012 and December 2016 were retrospectively reviewed. Thirty-two patients were included. Demographic, clinical, treatment, and outcome data were analyzed. Results: The median age of the patients was 34.5 years. The most common presentation was unilateral painless testicular mass (87.5%). Seminoma represented 53% of cases and almost half of them had Stage I disease. For all patients, the clinical stage and International Germ Cell Cancer Collaborative Group (IGCCC) risk classification were significantly associated with survival outcomes. Five-year overall survival for stage I patients was 100%, compared to 87.5% for stage II (p < 0.0001). Patients with good risk had a 5-year OS of 87.4% while none of the poor risk group survived for 5 years (p =0.002). The 5-year disease-free survival for stage I was 83% for those who remained under active surveillance versus 87.5% for those who received adjuvant carboplatin (p=0.364). Conclusions: Stage I TGCTs has an excellent overall survival regardless of the treatment modality received. In advanced disease, the clinical stage and IGCCC risk stratification remain valid prognostic risk factors.
      PubDate: Tue, 30 Nov 2021 22:00:00 +010
       
  • Gastrointestinal Stromal Tumor: Clinicopathological Features, Management,
           and Comparison of ...

    • Abstract: Background: Gastrointestinal stromal tumor (GIST) is the most common mesenchymal neoplasm of the gastrointestinal tract. To optimize its management, different risk stratification schemes had been developed for GIST. Aim:To describe the clinicopathological profile and management of GIST and to evaluate three different GIST risk stratification schemes. Methods: Retrospective review of patients treated in a single Egyptian center during an 11-year period. High-risk GIST was identified using three different risk stratification schemes; the Armed Forces Institute of Pathology (AFIP) scheme, the National Institute of Health (NIH) consensus scheme and the American Joint Committee on Cancer (AJCC) TNM staging system. Results: The disease extent at the presentation of 34 patients was localized in 19 (56%), locally advanced in 4 (12%) and metastatic in 11 (32%). Twenty-one (62%) underwent surgery and achieved complete remission. Their median overall survival was not reached. The median disease-free survival (DFS) was 58.2 months (95%CI: 28.8 – 58.2) and the 3-year rate was 66%. Non-gastric GIST, larger tumors (>10cm) and high mitotic index (>5 / 50 HPF) was associated with shorter DFS (p = 0.146, 0.047 and 0.06, respectively). The AFIP, NIH consensus and AJCC TNM risk stratification methods identified high-risk groups that had a significantly shorter median DFS than lower-risk groups (p = 0.022, 0.009 and 0.22, respectively). Conclusion: All the studied three risk stratification schemes categorized a high-risk group with significantly poorer outcome. According to the information available, any of these schemes may be used in identifying high-risk GIST.
      PubDate: Tue, 30 Nov 2021 22:00:00 +010
       
  • COVID-19 Infection in Patients with Chronic Lymphocytic Leukemia: Report
           of Two Cases and ...

    • Abstract: Chronic lymphocytic leukemia (CLL) typically occurs in the elderly and has a highly variable clinical course. Infectious complications have been known to be a major cause of morbidity and mortality in CLL patients. The management of hematological malignancies, including CLL, during the COVID-19 pandemic is challenging. Here we describe two patients with CLL who got infected with SARS-COV-2 as confirmed by positive nasopharyngeal swab PCR. The 1st patient, who was receiving treatment for CLL-associated autoimmune hemolytic anemia, was hospitalized with mild COVID-19 symptoms. The 2nd patient, who was on active treatment for CLL, had asymptomatic COVID-19 infection and was not hospitalized. Both patients recovered from COVID-19 without related complications.
      PubDate: Tue, 30 Nov 2021 22:00:00 +010
       
 
JournalTOCs
School of Mathematical and Computer Sciences
Heriot-Watt University
Edinburgh, EH14 4AS, UK
Email: journaltocs@hw.ac.uk
Tel: +00 44 (0)131 4513762
 


Your IP address: 3.238.176.43
 
Home (Search)
API
About JournalTOCs
News (blog, publications)
JournalTOCs on Twitter   JournalTOCs on Facebook

JournalTOCs © 2009-